This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chlebowski, R. T. Articles by Pfister, D. G. Search for Related Content PubMed PubMed Citation Articles by Chlebowski, R. T. Articles by Pfister, D. G. Social Bookmarking                            What's this?

American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene

From the American Society of Clinical Oncology, Alexandria, VA.

Address reprint requests to American Society of Clinical Oncology, Health Services Research Department, 225 Reinekers Lane, Suite 650, Alexandria, VA 22314; email guidelines{at}asco.org

ABSTRACT

OBJECTIVE: To conduct an evidence-based technology assessment to determine whether tamoxifen and raloxifene as breast cancer risk-reduction strategies are appropriate for broad-based conventional use in clinical practice.

POTENTIAL INTERVENTION: Tamoxifen and raloxifene.

OUTCOME: Outcomes of interest include breast cancer incidence, breast cancer-specific survival, overall survival, and net health benefits.

EVIDENCE: A comprehensive, formal literature review was conducted for tamoxifen and raloxifene on the following topics: breast cancer risk reduction; tamoxifen side effects and toxicity, including endometrial cancer risk; tamoxifen influences on nonmalignant diseases, including coronary heart disease and osteoporosis; and decision making by women at risk for breast cancer. Testimony was collected from invited experts and interested parties.

VALUES: More weight was given to publications that described randomized trials.

BENEFITS/HARMS/COSTS: The American Society of Clinical Oncology (ASCO) Working Group acknowledges that a woman's decision regarding breast cancer risk-reduction strategies will depend on the importance and weight attributed to the information provided regarding both cancer and non–cancer-related risks.

CONCLUSIONS: For women with a defined 5-year projected risk of breast cancer of 1.66%, tamoxifen (at 20 mg/d for up to 5 years) may be offered to reduce their risk. It is premature to recommend raloxifene use to lower the risk of developing breast cancer outside of a clinical trial setting. On the basis of available information, use of raloxifene should currently be reserved for its approved indication to prevent bone loss in postmenopausal women. Conclusions are based on single-agent use of the drugs. At the present time, the effect of using tamoxifen or raloxifene with other medications (such as hormone replacement therapy), or using tamoxifen and raloxifene in combination or sequentially, has not been studied adequately. The continuing use of placebo-controlled trials in other risk-reduction trials highlights the current unanswered issues concerning the use of such interventions, especially when the influence on net health benefit remains to be determined. Breast cancer risk reduction is a rapidly evolving area. This technology assessment represents an ongoing process with existing plans to monitor and review data and to update recommendations in a timely matter. (See Table 1 for a summary of conclusions.)

VALIDATION: The conclusions of the Working Group were evaluated by the ASCO Health Services Research Committee and by the ASCO Board of Directors.

SPONSOR: American Society of Clinical Oncology.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Visvanathan, R. T. Chlebowski, P. Hurley, N. F. Col, M. Ropka, D. Collyar, M. Morrow, C. Runowicz, K. I. Pritchard, K. Hagerty, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction J. Clin. Oncol., July 1, 2009; 27(19): 3235 - 3258. [Abstract] [Full Text] [PDF]

				H. Janes, M. S. Pepe, and W. Gu Assessing the Value of Risk Predictions by Using Risk Stratification Tables Ann Intern Med, November 18, 2008; 149(10): 751 - 760. [Abstract] [Full Text] [PDF]

				J. J. Dignam and M. N. Kocherginsky Choice and Interpretation of Statistical Tests Used When Competing Risks Are Present J. Clin. Oncol., August 20, 2008; 26(24): 4027 - 4034. [Abstract] [Full Text] [PDF]

				H. Kennecke, I. Olivotto, C Speers, B Norris, S. Chia, C Bryce, and K. Gelmon Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen Ann. Onc., January 1, 2007; 18(1): 45 - 51. [Abstract] [Full Text] [PDF]

				R. J. Santen and R. Mansel Benign Breast Disorders N. Engl. J. Med., July 21, 2005; 353(3): 275 - 285. [Full Text] [PDF]

				C J Fabian, B F Kimler, M S Mayo, and S A Khan Breast-tissue sampling for risk assessment and prevention Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213. [Abstract] [Full Text] [PDF]

				C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]

				B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]

				B. Arun Ductal Lavage and Risk Assessment of Breast Cancer Oncologist, November 1, 2004; 9(6): 599 - 605. [Abstract] [Full Text] [PDF]

				C. L. Lewis, L. S. Kinsinger, R. P. Harris, and R. J. Schwartz Breast Cancer Risk in Primary Care: Implications for Chemoprevention Arch Intern Med, September 27, 2004; 164(17): 1897 - 1903. [Abstract] [Full Text] [PDF]

				J. Fosket Constructing "High-Risk Women": The Development and Standardization of a Breast Cancer Risk Assessment Tool Science Technology Human Values, July 1, 2004; 29(3): 291 - 313. [Abstract] [PDF]

				C. E. Holmes and H. B. Muss Diagnosis and Treatment of Breast Cancer in the Elderly CA Cancer J Clin, July 1, 2003; 53(4): 227 - 244. [Abstract] [Full Text]

				R. J Cersosimo Tamoxifen for Prevention of Breast Cancer Ann. Pharmacother., February 1, 2003; 37(2): 268 - 273. [Abstract] [Full Text] [PDF]

				R. Jakesz, H. Hausmaninger, E. Kubista, M. Gnant, C. Menzel, T. Bauernhofer, M. Seifert, K. Haider, B. Mlineritsch, P. Steindorfer, et al. Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5 J. Clin. Oncol., December 15, 2002; 20(24): 4621 - 4627. [Abstract] [Full Text] [PDF]

				N. F. Col, R. J. Goldberg, R. K. Orr, J. K. Erban, J. M. Fortin, and R. T. Chlebowski Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model Med Decis Making, October 1, 2002; 22(5): 386 - 393. [Abstract] [PDF]

				F. Cucinelli, L. Soranna, D. Romualdi, G. Muzj, S. Mancuso, and A. Lanzone The Effect of Raloxifene on Glyco-Insulinemic Homeostasis in Healthy Postmenopausal Women: A Randomized Placebo-Controlled Study J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4186 - 4192. [Abstract] [Full Text] [PDF]

				E. P. Winer, C. Hudis, H. J. Burstein, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, J. Gralow, L. J. Goldstein, K. I. Pritchard, et al. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002 J. Clin. Oncol., August 1, 2002; 20(15): 3317 - 3327. [Abstract] [Full Text] [PDF]

				R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343. [Abstract] [Full Text] [PDF]

				U.S. Preventive Services Task Force* Chemoprevention of Breast Cancer: Recommendations and Rationale Ann Intern Med, July 2, 2002; 137(1): 56 - 58. [Abstract] [Full Text] [PDF]

				T. Ernst, L. Chang, D. Cooray, C. Salvador, J. Jovicich, I. Walot, K. Boone, and R. Chlebowski The Effects of Tamoxifen and Estrogen on Brain Metabolism in Elderly Women J Natl Cancer Inst, April 17, 2002; 94(8): 592 - 597. [Abstract] [Full Text] [PDF]

				T. J. Powles Breast Cancer Prevention Oncologist, February 1, 2002; 7(1): 60 - 64. [Abstract] [Full Text] [PDF]

				S. R. Cummings, T. Duong, E. Kenyon, J. A. Cauley, M. Whitehead, K. A. Krueger, and for the Multiple Outcomes of Raloxifene Evaluation Serum Estradiol Level and Risk of Breast Cancer During Treatment With Raloxifene JAMA, January 9, 2002; 287(2): 216 - 220. [Abstract] [Full Text] [PDF]

				National Institutes of Health Consensus Developmen National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 5 - 15. [Abstract] [Full Text] [PDF]

				M. Stefanek, L. Hartmann, and W. Nelson Risk-Reduction Mastectomy: Clinical Issues and Research Needs J Natl Cancer Inst, September 5, 2001; 93(17): 1297 - 1297. [Abstract] [Full Text] [PDF]

				I. Kuter Breast Cancer Oncologist, August 1, 2001; 6(4): 338 - 346. [Abstract] [Full Text] [PDF]

				National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 J Natl Cancer Inst, July 4, 2001; 93(13): 979 - 989. [Abstract] [Full Text] [PDF]

				M. Levine, J.-M. Moutquin, R. Walton, and J. Feightner Chemoprevention of breast cancer: A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer Can. Med. Assoc. J., June 1, 2001; 164(12): 1681 - 1690. [Abstract] [Full Text]

				C. K. Osborne and S. A. W. Fuqua Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use J. Clin. Oncol., September 17, 2000; 18(17): 3172 - 3186. [Abstract] [Full Text] [PDF]

				R. T. Chlebowski Reducing the Risk of Breast Cancer N. Engl. J. Med., July 20, 2000; 343(3): 191 - 198. [Full Text] [PDF]

				S. M. Lippman and P. H. Brown RESPONSE: Re: Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost J Natl Cancer Inst, April 19, 2000; 92(8): 658 - 658. [Full Text] [PDF]

				B. E. Hillner, J. N. Ingle, J. R. Berenson, N. A. Janjan, K. S. Albain, A. Lipton, G. Yee, J. S. Biermann, R. T. Chlebowski, and D. G. Pfister American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer J. Clin. Oncol., March 13, 2000; 18(6): 1378 - 1391. [Abstract] [Full Text] [PDF]

				K. Armstrong, A. Eisen, and B. Weber Assessing the Risk of Breast Cancer N. Engl. J. Med., February 24, 2000; 342(8): 564 - 571. [Full Text] [PDF]

				S. M. Lippman and P. H. Brown Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost J Natl Cancer Inst, November 3, 1999; 91(21): 1809 - 1819. [Full Text] [PDF]

				W. McCaskill-Stevens, E. T. Hawk, P. J. Flynn, and S. M. Lippman National Cancer Institute-Supported Cancer Chemoprevention Research: Coming of Age J. Clin. Oncol., November 1, 1999; 17(90001): 53 - 62. [Full Text] [PDF]

				I. Kuter Breast Cancer Highlights Oncologist, August 1, 1999; 4(4): 299 - 308. [Full Text]